MedTrace Logo

eVusheld Assessment reaL wORld Effectiveness in Israel Clalit Health Services

NCT05712096 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 4000

Last updated 2025-01-21

No results posted yet for this study

Summary

An AstraZeneca-sponsored observational, electronic healthcare record (EHR)-embedded retrospective cohort study to assess the real-world effectiveness of EVUSHELD against SARS-CoV-2 infection, COVID-19-related hospitalization, and other COVID-19 related outcomes in the total EVUSHELD eligible patient population in the Clalit Health Services in Israel.

Conditions

Interventions

DRUG

EVUSHELD

EVUSHELD (AZD 7442, Tixagévimab/Cilgavimab)

Sponsors & Collaborators

  • Clalit Health Services

    collaborator OTHER

  • AstraZeneca

    lead INDUSTRY

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-03-09
Primary Completion
2023-05-30
Completion
2023-05-30
FDA Drug
Yes

Countries

  • Israel

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05712096 on ClinicalTrials.gov